Announcement PDF ASX Announcement Percheron Therapeutics Limited ABN 41 095 060 745 ASX: PER | FSE: AWY | US OTC: ATHJY RESULTS OF ANNUAL GENERAL MEETING Melbourne, Australia – 22 October 2025: Percheron Therapeutics Limited (ASX:PER or “the Company”) is pleased to advise the results of today’s Annual General Meeting of shareholders. In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, the results of the Annual General Meeting are set out in the attached report and include a summary of the poll voting results by proxies on each resolution considered at the Annual General Meeting. All resolutions to be voted on at the meeting were decided on a poll. As more than 75% of votes cast on Resolution 1 supported the adoption of the 2025 Remuneration Report, Resolution 7 (the Conditional Spill Resolution) was withdrawn The Board thanks shareholder for their attendance and participation at the Annual General Meeting. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well tolerated, and Percheron aims to commence further clinical trials in CY2026. For further information, please see our website at www.PercheronTx.com, or email info@PercheronTx.com. This announcement has been authorised for release to the Australian Securities Exchange by the Board of Directors. The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution Result If s250U applies Resolution Resolution Type For Against Proxy's Discretion Abstain For Against Abstain* Carried / Not Carried 243,924,127 45,241,387 20,803,602 791,419 264,727,729 45,241,387 791,419 78.69% 14.60% 6.71% 85.40% 14.60% 321,705,380 572,845 12,258,263 37,776,546 333,963,643 572,845 37,776,546 96.16% 0.17% 3.66% 99.83% 0.17% 282,914,880 7,696,466 21,995,238 507,150 304,910,118 7,696,466 507,150 90.50% 2.46% 7.04% 97.54% 2.46% 304,418,234 45,511,048 21,103,602 1,280,150 325,521,836 45,511,048 1,280,150 82.05% 12.27% 5.69% 87.73% 12.27% 304,919,689 44,927,357 21,880,238 585,750 326,799,927 44,927,357 585,750 82.03% 12.09% 5.89% 87.91% 12.09% 313,669,492 36,777,854 21,139,938 725,750 334,809,430 36,777,854 725,750 84.41% 9.90% 5.69% 90.10% 9.90% 45,414,563 254,725,476 9,653,346 967,150 14.66% 82.22% 3.12% * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. Carried N/A 7. Spill Resolution (conditional resolution) Ordinary 5. Amendments to Constitution (special resolution) Special Carried N/A 6. Re-insertion of Proportional Takeover Bid Approval Provisions (special resolution) Special 3. Ratification of Prior Issue of Tranche 2 Shares to Institutional Investors Ordinary Carried N/A 4. Approval of 10% Placement Facility (special resolution) Special Carried N/A 1. Adoption of the 2025 Remuneration Report (non- binding) Ordinary Carried NO 2. Re-Election of Director – Dr Charmaine Gittleson Ordinary Carried N/A Percheron Therapeutics Limited Annual General Meeting Wednesday, 22 October 2025 Results of Meeting Resolution details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll (where applicable) Resolution 7 - Spill Resolution has been WITHDRAWN